What Is eGFR (Estimated Glomerular Filtration Rate)? Normal vs Optimal Range Explained

eGFR is the single most important number for kidney health assessment—it translates a raw creatinine value into a functional measure of filtration capacity that accounts for the patient's age, sex, and body size. The KDIGO staging system uses eGFR to classify chronic kidney disease: stage 1 (eGFR above 90 with evidence of kidney damage), stage 2 (60–89), stage 3a (45–59), stage 3b (30–44), stage 4 (15–29), and stage 5 (below 15, requiring dialysis or transplant consideration). The CTD catalogs over 2,400 compound interactions with glomerular filtration-related genes, reflecting the massive pharmacological impact on kidney function from commonly prescribed medications. An eGFR of 70 in a 30-year-old is far more concerning than 70 in a 75-year-old, because some decline with normal aging is expected—approximately 1 mL/min/year after age 40. Trending eGFR across at least three measurements over twelve months establishes the personal slope of decline, which is far more clinically actionable than interpreting any single value in isolation.

PubMed indexes over 85,000 clinical publications on eGFR, making it one of the most extensively validated calculated biomarkers in medicine. The CKD-EPI equation (2021 update, which removed the race coefficient) calculates eGFR from serum creatinine, age, and sex. An important limitation: eGFR from creatinine is unreliable in people with extreme muscle mass (very high or very low), acute kidney injury (where creatinine hasn't reached steady state), and during pregnancy (where increased blood volume dilutes creatinine). FAERS pharmacovigilance data document eGFR decline as a reported outcome for over 500 medications, including NSAIDs, aminoglycosides, IV contrast dye, cisplatin, lithium, and proton pump inhibitors. Medication review is one of the most actionable interventions for patients with declining eGFR.

The slope of eGFR decline over time is more clinically meaningful than any single measurement. A rapid decline—defined as losing more than 5 mL/min/1.73m² per year—signals aggressive kidney disease that requires urgent investigation and intervention. Normal age-related decline runs approximately 0.5–1.0 mL/min/year. A stable eGFR of 55 over three years in a 70-year-old is far less concerning than an eGFR that drops from 85 to 55 over the same period in a 45-year-old. Hyperfiltration—eGFR above 120 mL/min—can paradoxically signal early diabetic nephropathy, where the kidneys are working too hard under glucose-driven osmotic pressure before eventually burning out and declining. Catching this early hyperfiltration phase in diabetic patients provides the best window for nephroprotective intervention with SGLT2 inhibitors and ACE inhibitors, the two pharmacological pillars of kidney preservation.